Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 3/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13603918 | 0.88 | NPSR1 (0.44) | MEN1KMT2ATSHRALDH1A1NPC1 | |
| SCHEMBL11562585 | 0.86 | ALDH1A1 (0.52) | MEN1KMT2ATSHRALDH1A1NPC1 | |
| Diethylaniline SCHEMBL28333434 | 0.86 | MEN1 (0.59) | MEN1KMT2ATSHRALDH1A1NPC1 | |
| SCHEMBL1132513 | 0.84 | ALDH1A1 (0.53) | MEN1KMT2ATSHRALDH1A1NPC1 | |
| SCHEMBL2157377 | 0.83 | ALDH1A1 (0.64) | MEN1KMT2ATSHRALDH1A1NPC1 | |
| Hydrochloric Acid SCHEMBL8226907 | 0.82 | ALDH1A1 (0.52) | MEN1KMT2ATSHRALDH1A1NPC1 | |
| SCHEMBL13644987 | 0.82 | TDP1 (0.47) | MEN1KMT2ATSHRALDH1A1NPC1 | |
| SCHEMBL7439082 | 0.82 | CNR2 (0.46) | MEN1KMT2ATSHRALDH1A1NPC1 | |
| SCHEMBL22026428 | 0.81 | AOC3 (0.54) | MEN1KMT2ATSHRALDH1A1NPC1 | |
| SCHEMBL3868884 | 0.81 | MEN1 (0.47) | MEN1KMT2ATSHRALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM THERAPEUTICS LLC | 2011-03-17 | — | — | US | claimed |
| CN-101686952-A | Novel agents of calcium ion channel modulators | VM DISCOVERY INC | 2010-03-31 | — | — | CN | claimed |
| EP-2073799-A2 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM Discovery, Inc. (US) | 2009-07-01 | — | — | EP | claimed |
| WO-2008112715-A2 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM DISCOVERY INC. (US) | 2008-09-18 | — | — | WO | claimed |
| EP-1931645-A2 | N- (3-AMINO-QUINOXALIN-2-YL) -SULFONAMIDE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | Exelixis, Inc. (US) | 2008-06-18 | — | — | EP | claimed |
| WO-2007044729-A2 | N- (3-AMINO-QUINOXALIN-2-YL) -SULFONAMIDE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | claimed |
| EP-0942924-A2 | METHODS AND COMPOUNDS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 1999-09-22 | — | — | EP | claimed |
| WO-1998022494-A9 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | — | 1998-08-20 | — | — | WO | claimed |
| WO-1998022494-A2 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | claimed |
| US-8586619-B2 | Agents of calcium ion channel modulators | VM THERAPEUTICS LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM THERAPEUTICS LLC | 2011-03-17 | — | — | US | disclosed |
| CN-101686952-A | Novel agents of calcium ion channel modulators | VM DISCOVERY INC | 2010-03-31 | — | — | CN | disclosed |
| US-20100075993-A1 | SMALL MOLECULE INHIBITORS AGAINST WEST NILE VIRUS REPLICATION | DREXEL UNIVERSITY (US) | 2010-03-25 | — | — | US | disclosed |
| EP-2073799-A2 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM Discovery, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-2056829-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | Exelixis, Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008112715-A2 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM DISCOVERY INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| EP-0714885-B1 | Preparation process of aminoacetamide derivative | EISAI CO LTD (JP) | 1999-09-01 | — | — | EP | disclosed |
| EP-0714885-A2 | Preparation process of aminoacetamide derivative | EISAI CHEMICAL CO., LTD. (JP) | 1996-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075993-A1 | SMALL MOLECULE INHIBITORS AGAINST WEST NILE VIRUS REPLICATION | MAVS, ZC3HAV1, KDM4E | MEN1 3272/4885KMT2A 46/4885TSHR 4741/4885 |
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | CACNA1G, CACNA1C, CACNA1B | MEN1 3058/4885KMT2A 3399/4885TSHR 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.